UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Anti-cancer drug design, ISSN 0266-9536, 1985
Journal
2009, ISBN 9781603270861, xxviii, 637
Book
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 1978
Journal
Cancer chemotherapy and pharmacology, ISSN 0344-5704, 8/2011, Volume 68, Issue 2, pp. 445 - 455
Fisetin | Lewis lung carcinoma | Angiogenesis | Antitumour activity | Cyclophosphamide | Medicine & Public Health | Cancer Research | Oncology | Cytotoxicity | EA·hy 926 endothelial cells | Pharmacology/Toxicology | Flavonoid | EA•hy 926 endothelial cells | Pharmacology & Pharmacy | Life Sciences & Biomedicine | Science & Technology | Tumors of the respiratory system and mediastinum | Biological and medical sciences | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Pneumology | NIH 3T3 Cells | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Tubulin Modulators - pharmacology | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents, Alkylating - pharmacology | Flavonoids - adverse effects | Antineoplastic Agents, Alkylating - administration & dosage | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Flavonoids - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Angiogenesis Inhibitors - administration & dosage | Antineoplastic Agents, Phytogenic - administration & dosage | Angiogenesis Inhibitors - therapeutic use | Flavonoids - administration & dosage | Tubulin Modulators - administration & dosage | Female | Flavonoids - pharmacology | Antineoplastic Agents, Phytogenic - therapeutic use | Angiogenesis Inhibitors - adverse effects | Antineoplastic Agents, Phytogenic - adverse effects | Cell Line | Cell Survival - drug effects | Tubulin Modulators - adverse effects | Mice, Inbred C57BL | Angiogenesis Inhibitors - pharmacology | Tubulin Modulators - therapeutic use | Carcinoma, Lewis Lung - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Cell Movement - drug effects | Animals | Tumor Burden - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endothelial Cells - cytology | Neovascularization, Pathologic - drug therapy | Cyclophosphamide - pharmacology | Carcinoma, Lewis Lung - pathology | Cell Proliferation - drug effects | Mice | Antineoplastic Agents, Alkylating - adverse effects | Antineoplastic Agents, Phytogenic - pharmacology | Cell Cycle - drug effects | Endothelial Cells - drug effects | Antimitotic agents | Flavonoids | Flavones | Lung cancer | Bioflavonoids | Accountants | Drug therapy, Combination | Universities and colleges | Endothelium | Tumors | Index Medicus | cytology | Antineoplastic Agents, Phytogenic | pathology | Cell Proliferation | Endothelial Cells | Tubulin Modulators | Neovascularization, Pathologic | fisetin | administration & dosage | pharmacology | flavonoid | Carcinoma, Lewis Lung | Antineoplastic Agents, Alkylating | cytotoxicity | drug therapy | Cell Survival | angiogenesis | Antineoplastic Combined Chemotherapy Protocols | drug effects | Tumor Burden | Angiogenesis Inhibitors | EA.hy 926 | Cell Cycle | antitumour activity | adverse effects | therapeutic use | Cell Movement
Journal Article
Anti-cancer drugs, ISSN 0959-4973, 1990
Journal
01/2014, ISBN 9783110345940
Book
Molecular cancer therapeutics, ISSN 1535-7163, 2001
Journal
Blood, ISSN 0006-4971, 05/2014, Volume 123, Issue 21, pp. 3239 - 3246
Life Sciences & Biomedicine | Hematology | Science & Technology | Daunorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Cytarabine - therapeutic use | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Cytarabine - adverse effects | Cytarabine - administration & dosage | Antimetabolites, Antineoplastic - administration & dosage | Daunorubicin - adverse effects | Antibiotics, Antineoplastic - administration & dosage | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antimetabolites, Antineoplastic - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Female | Aged | Liposomes | Daunorubicin - administration & dosage | Index Medicus | Abridged Index Medicus | 33 | 8 | Clinical Trials and Observations | 29
Journal Article
Journal of clinical oncology, ISSN 0732-183X, 11/2009, Volume 27, Issue 33, pp. 5538 - 5546
Life Sciences & Biomedicine | Oncology | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Postmenopause - drug effects | Receptors, Estrogen - metabolism | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carcinoma - mortality | Receptors, Progesterone - genetics | Breast Neoplasms - metabolism | Receptors, Progesterone - metabolism | Dose-Response Relationship, Drug | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Invasiveness - pathology | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Carcinoma - pathology | Carcinoma - secondary | Carcinoma - drug therapy | Receptors, Estrogen - genetics | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Biomarkers, Tumor - analysis | Antineoplastic Agents, Hormonal - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Maximum Tolerated Dose | Breast Neoplasms - pathology | Quinazolines - adverse effects | Survival Analysis | Breast Neoplasms - mortality | Aged | Biomarkers, Tumor - genetics | Carcinoma - metabolism | Neoplasm Staging | Nitriles - adverse effects | Index Medicus | Carcinoma | Quinazolines | Breast Neoplasms | Life Sciences | Immunology | Triazoles | Postmenopause | Nitriles | Antineoplastic Agents, Hormonal | Tumor Markers, Biological | Receptors, Estrogen | Neoplasm Invasiveness | Antineoplastic Combined Chemotherapy Protocols | Receptor, erbB-2 | Receptors, Progesterone | Kaplan-Meiers Estimate
Journal Article
The New England journal of medicine, ISSN 0028-4793, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
2007, ISBN 9780195187762, ix, 355
Book
European journal of medicinal chemistry, ISSN 0223-5234, 10/2014, Volume 85, pp. 418 - 437
Inhibitor | Cross-coupling reaction | DNPH1 | Nucleoside analogues | Crystal structure | Cancer | Purine Nucleotides - pharmacology | Antineoplastic Agents - chemical synthesis | Humans | Proto-Oncogene Proteins - chemistry | Structure-Activity Relationship | Enzyme Inhibitors - chemical synthesis | Molecular Targeted Therapy | Purine Nucleotides - chemistry | N-Glycosyl Hydrolases - chemistry | Purine Nucleotides - metabolism | Antineoplastic Agents - metabolism | Enzyme Inhibitors - chemistry | Drug Design | Antineoplastic Agents - pharmacology | Proto-Oncogene Proteins - metabolism | Proto-Oncogene Proteins - antagonists & inhibitors | Chemistry Techniques, Synthetic | Enzyme Inhibitors - metabolism | N-Glycosyl Hydrolases - antagonists & inhibitors | Enzyme Inhibitors - pharmacology | Rats | Nuclear Proteins - metabolism | Purine Nucleotides - chemical synthesis | Antineoplastic Agents - chemistry | Nuclear Proteins - chemistry | N-Glycosyl Hydrolases - metabolism | Animals | Nuclear Proteins - antagonists & inhibitors | Cell Line, Tumor | Protein Conformation | Molecular Docking Simulation | Drug Screening Assays, Antitumor | Enzymes | Colon cancer | Leukemia | Crystals | Hydrolases | Nucleotides | Structure | Index Medicus | Nuclear Proteins/chemistry | Purine Nucleotides/metabolism | Proto-Oncogene Proteins/antagonists & inhibitors | Enzyme Inhibitors/metabolism | Enzyme Inhibitors/pharmacology | Life Sciences | Antineoplastic Agents/pharmacology | N-Glycosyl Hydrolases/antagonists & inhibitors | Nuclear Proteins/antagonists & inhibitors | N-Glycosyl Hydrolases/metabolism | Nuclear Proteins/metabolism | Purine Nucleotides/chemistry | Enzyme Inhibitors/chemistry | Purine Nucleotides/chemical synthesis | Enzyme Inhibitors/chemical synthesis | Antineoplastic Agents/metabolism | N-Glycosyl Hydrolases/chemistry | Proto-Oncogene Proteins/chemistry | Biochemistry, Molecular Biology | Proto-Oncogene Proteins/metabolism | Purine Nucleotides/pharmacology | Antineoplastic Agents/chemistry | Antineoplastic Agents/chemical synthesis
Journal Article
Annals of oncology, ISSN 0923-7534, 12/2012, Volume 23, Issue 12, pp. 3069 - 3074
luminal breast cancer | neoadjuvant | hormonotherapy | chemotherapy | Neoadjuvant | Chemotherapy | Hormonotherapy | Luminal breast cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Gynecology. Andrology. Obstetrics | Mammary gland diseases | Pharmacology. Drug treatments | Biological and medical sciences | Medical sciences | Antineoplastic agents | Tumors | Receptors, Estrogen - metabolism | Humans | Middle Aged | Antibiotics, Antineoplastic - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Ki-67 Antigen - metabolism | Antineoplastic Agents - therapeutic use | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Receptors, Progesterone - metabolism | Taxoids - therapeutic use | Antineoplastic Agents - adverse effects | Antineoplastic Agents, Hormonal - therapeutic use | Adult | Female | Taxoids - adverse effects | ErbB Receptors - metabolism | Docetaxel | Treatment Outcome | Breast Neoplasms - drug therapy | Antineoplastic Agents, Alkylating - therapeutic use | Disease-Free Survival | Antibiotics, Antineoplastic - therapeutic use | Keratin-8 - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Keratin-18 - metabolism | Neoadjuvant Therapy - adverse effects | Epirubicin - therapeutic use | Aged | Antineoplastic Agents, Alkylating - adverse effects | Epirubicin - adverse effects | Index Medicus
Journal Article
Science (American Association for the Advancement of Science), ISSN 0036-8075, 5/2010, Volume 328, Issue 5981, pp. 1031 - 1035
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Biological and medical sciences | Chemotherapy | Medical sciences | Antineoplastic agents | Pharmacology. Drug treatments | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Drug therapy | Health aspects | Index Medicus | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article